In contrast, GLP-2 analogs have been developed to treat gastrointestinal (GI)-related disorders, such as short bowel syndrome (SBS), inflammatory bowel disease (IBD), and chemotherapeutically induced GI mucositis, largely due to the intestinotrophic effects of GLP-2 in the GI tract [26]. This evidence concerns the gene GCG and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.